Price
No data yet.
Social Signal Score
Analyst Ratings
11 analystsRevenue
$243.60MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Sanj K. Patel
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Employees
- 366
- Beta
- 0.09
- Country
- GB
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 16.03
Financials
Revenue
$243.60M+3062.0%Net Income
$25.43MEBITDA
$27.67MFree Cash Flow
$46.80MEPS (diluted)
$0.30Shares Outstanding (diluted)
83.40M+156.9%Operating Expenses
$104.77MCash & Debt
$525.93MReturn of Capital
$316.0KRevenue by Segment (annual)
$677.56MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $677.56M | $59.01M | $0.80 |
| 2024 | $423.24M | $-43.19M | $-0.60 |
| 2023 | $270.26M | $14.08M | $0.20 |
| 2022 | $220.18M | $183.36M | $2.64 |
| 2021 | $38.54M | $-157.92M | $-2.30 |
| 2020 | $0.00 | $-161.38M | $-2.61 |
| 2019 | $0.00 | $-161.87M | $-2.99 |
| 2018 | $0.00 | $-103.23M | $-3.49 |
| 2017 | $0.00 | $-64.87M | $-2.00 |
| 2016 | $0.00 | $-23.97M | $-0.74 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $1.17
- Implied price
- $60.76
- Return from $79.27
- -5.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $30.21 — -61.9% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 36 | 44 | 52 | 60 | 68 |
|---|---|---|---|---|---|
| -2.0% | -20.1% | -16.8% | -14.0% | -11.5% | -9.2% |
| 3.0% | -16.0% | -12.5% | -9.6% | -6.9% | -4.6% |
| 8.0% | -11.9% | -8.3% | -5.2% | -2.4% | 0.0% |
| 13.0% | -7.8% | -4.1% | -0.8% | 2.1% | 4.7% |
| 18.0% | -3.7% | 0.2% | 3.6% | 6.6% | 9.3% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (2)
- Newszacks.com·6h ago·Neutral
Kiniksa Pharmaceuticals Stock Rallies 41% in Three Months: Here's Why KNSA is gaining momentum as Arcalyst sales surge and pipeline advances strengthen prospects for continued growth.
View source ↗ - Newsglobenewswire.com·13d ago·Neutral
Kiniksa Pharmaceuticals to Present at Wells Fargo 21st Annual Healthcare Conference LONDON, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026 at 8:45 a.m. Eastern Time.
View source ↗
Earnings
Tue, Oct 27(in 6 weeks)
Consensus estimate $0.39 per share
Typical surprise +0.2% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Jul 28$0.30 vs $0.30beat
- Tue, Apr 28$0.27 vs $0.18beat
- Tue, Feb 24$0.17 vs $0.29miss
- Tue, Oct 28$0.23 vs $0.33miss
- Tue, Jul 29$0.23 vs $0.18beat
- Tue, Apr 29$0.11 vs $0.02beat
Estimates and results for KNSA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KNSA officers and directors.
- Bought
- —
- Sold
- $3.8m
0 trades
4 trades
- Megna Michael Rsold
- Cole G Bradleysold
- Paolini John F.sold
- Paolini John F.sold
96 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KNSA.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.